ANCHOR LEAD: ONE GROUP OF PEOPLE WITH STAGE 2 COLON CANCER NEED TO AVOID CHEMOTHERAPY, ELIZABETH TRACEY REPORTS
Just like the treatment options for breast cancer, colon cancer treatment is now becoming more complex, with a recent study showing that patients with certain specific tumor characteristics will actually experience harm from chemotherapy. Patrick Okolo, a gastroenterologist at Johns Hopkins, describes the findings.
OKOLO: What they’ve looked at are patients with stage 2 colon cancer who have a specific defect that is DMMR, that is, DNA mismatch repair, that is, who are not able to repair breaks in DNA. And in those patients who are very carefully followed, those who received chemotherapy which would be the standard of treatment, actually did worse than those who did not. Five year survival in the no chemotherapy group was as high as 93% and in the chemotherapy group 75% so in this very specific group chemotherapy was not a good thing for them. :33
All patients with colon cancer should be assessed for tumor characteristics. I’m Elizabeth Tracey reporting.